Loading
A phase 2 trial of Lorigerlimab in ovarian cancer and endometrial cancer, run by MacroGenics, now recruiting.
A Study of Lorigerlimab in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06730347 by MacroGenics, with 80 participants planned, started 2025-05-01 and due to reach its primary completion in 2027-07. Interventions recorded: Lorigerlimab. Conditions listed: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary. No results are recorded here; the registry entry is the source.